Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.

Ademuyiwa FO, Ellis MJ, Ma CX.

J Oncol. 2013;2013:219869. doi: 10.1155/2013/219869. Epub 2013 Aug 1.

PMID:
23983689
[PubMed]
Free PMC Article
2.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
3.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

PMID:
20549829
[PubMed - indexed for MEDLINE]
Free Article
4.

Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.

Nahleh Z.

Med Oncol. 2010 Jun;27(2):531-9. doi: 10.1007/s12032-009-9244-6. Epub 2009 Jun 10. Review.

PMID:
19513864
[PubMed - indexed for MEDLINE]
5.

Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.

Oliver RT.

Oncologist. 1996;1(4):278-279.

PMID:
10388003
[PubMed - as supplied by publisher]
Free Article
6.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

PMID:
17438091
[PubMed - indexed for MEDLINE]
Free Article
7.

Triple-negative breast cancer: an update on neoadjuvant clinical trials.

Amos KD, Adamo B, Anders CK.

Int J Breast Cancer. 2012;2012:385978. doi: 10.1155/2012/385978. Epub 2012 Jan 24.

PMID:
22461984
[PubMed]
Free PMC Article
8.

[Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].

Ma WY, Zhang P, Zhang BL, Wang X, Xu XZ, Zheng S, Wang JY, Cai RG, Yuan P, Ma F, Fan Y, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2012 Oct;34(10):770-4. doi: 10.3760/cma.j.issn.0253-3766.2012.10.011. Chinese.

PMID:
23291072
[PubMed - indexed for MEDLINE]
9.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
[PubMed - indexed for MEDLINE]
10.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
[PubMed - indexed for MEDLINE]
11.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

PMID:
23098527
[PubMed - indexed for MEDLINE]
Free Article
12.

Neoadjuvant chemotherapy for locally advanced breast cancer in a malaysian tertiary hospital.

Azrif M, Ibrahim J, Aslan NM, Fong KV, Ismail F.

Asian Pac J Cancer Prev. 2011;12(1):157-62.

PMID:
21517250
[PubMed - indexed for MEDLINE]
Free Article
13.

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.

Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.

Cancer. 2010 Mar 15;116(6):1431-9. doi: 10.1002/cncr.24876. Erratum in: Cancer. 2011 May 15;117(10):2238.

PMID:
20131351
[PubMed - indexed for MEDLINE]
Free Article
14.

Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.

von Minckwitz G, Loibl S, Maisch A, Untch M.

Breast. 2011 Oct;20 Suppl 3:S142-5. doi: 10.1016/S0960-9776(11)70312-5. Review.

PMID:
22015282
[PubMed - indexed for MEDLINE]
15.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

PMID:
19758440
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J.

Lancet. 2010 Jan 30;375(9712):377-84. doi: 10.1016/S0140-6736(09)61964-4.

PMID:
20113825
[PubMed - indexed for MEDLINE]
17.

Clinicopathological features and treatment strategy for triple-negative breast cancer.

Yamamoto Y, Iwase H.

Int J Clin Oncol. 2010 Aug;15(4):341-51. doi: 10.1007/s10147-010-0106-1. Epub 2010 Jul 15.

PMID:
20632057
[PubMed - indexed for MEDLINE]
18.

Current treatment options in triple negative breast cancer.

Rodler E, Korde L, Gralow J.

Breast Dis. 2010;32(1-2):99-122. doi: 10.3233/BD-2010-0304. Review.

PMID:
21778572
[PubMed - indexed for MEDLINE]
19.

Triple-negative breast cancer: adjuvant therapeutic options.

Gucalp A, Traina TA.

Chemother Res Pract. 2011;2011:696208. doi: 10.1155/2011/696208. Epub 2011 Jun 21.

PMID:
22312556
[PubMed]
Free PMC Article
20.

Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.

Medioni J, Huchon C, Le Frere-Belda MA, Hofmann H, Bats AS, Eme D, Andrieu JM, Oudard S, Lecuru F, Levy E.

Drugs R D. 2011;11(2):147-57. doi: 10.2165/11591210-000000000-00000.

PMID:
21679005
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk